Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma
Pedro Miguel Lacal, Maria Grazia Atzori, Federica Ruffini, Manuel Scimeca, Elena Bonanno, Rosella Cicconi, Maurizio Mattei, Roberta Bernardini, Stefania D’Atri, Lucio Tentori, Grazia Graziani
Topics & Concepts
Cancer researchVasculogenic mimicryMelanomaAngiogenesisTumor microenvironmentMonoclonal antibodyVascular endothelial growth factorIn vivoImmune systemImmunotherapyMyeloidProgenitor cellImmune checkpointMyeloid-derived Suppressor CellImmunologyMedicineAntibodyBiologyMetastasisCancerStem cellCell biologyInternal medicineSuppressorVEGF receptorsBiotechnologyImmune cells in cancerCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses